Isocarboxazid

Summary

Isocarboxazid (CHEMBL1201168) is an approved small molecule (ATC N06AF01); indicated across 2 conditions including major depressive disorder and alzheimer disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N06AF01
• Indications: 2 conditions
• Clinical trials: 1
• Chemistry: 231.25 Da · C12H13N3O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201168
Name	Isocarboxazid
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	3759
ATC	N06AF01
Molecular formula	C12H13N3O2
Molecular weight	231.25
InChIKey	XKFPYPQQHFEXRZ-UHFFFAOYSA-N

SMILES: CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2

IUPAC name: N’-benzyl-5-methyl-1,2-oxazole-3-carbohydrazide

Also known as: Enerzer, Isocarboxazid, Isocarboxazida, Isocarboxazide, Marplan, NSC-169893, SID11112152, SID56463226, ISOCARBOXAZID, isocarboxazid, ISOCARBOXAZIDE, SID144203887

Patent coverage: 3,659 distinct patent families (14,246 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Prelamin-A/C, Beta-lactamase, Prostaglandin G/H synthase 2, Cytochrome P450 1A2, Prostaglandin G/H synthase 1.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 5 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	5.5	Potency	3162	nM	CHEMBL_ACT_3644209

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
major depressive disorder	4	MONDO:0002009	MONDO:0002009
Alzheimer disease	0	MONDO:0004975	MONDO:0004975

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02323217	EARLY_PHASE1	COMPLETED	I2PETHV - Imidazoline2 Binding Site in Healthy Volunteers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).